Join
Live feed
·
INSIDERFilingvia Quantisnow
Vertex Pharmaceuticals Incorporated logo

EVP, Chief Scientific Officer Bunnage Mark E. sold $14,964 worth of shares (33 units at $453.45) as part of a pre-agreed trading plan, decreasing direct ownership by 0.45% to 7,284 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
VRTX· Vertex Pharmaceuticals Incorporated
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VRTX (Vertex Pharmaceuticals Incorporated) and more on Quantisnow.